Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
- 23 October 2013
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 63 (6), 520-527
- https://doi.org/10.1016/j.jacc.2013.09.042
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin TherapyCirculation, 2013
- Genetic Associations with Valvular Calcification and Aortic StenosisThe New England Journal of Medicine, 2013
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJama-Journal Of The American Medical Association, 2009
- Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular OutcomesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseThe New England Journal of Medicine, 2004
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Association between lipoprotein(a) and progression of coronary artery disease in middle-aged menThe American Journal of Cardiology, 1994
- Apolipoproteins and ischaemic heart disease: implications for screeningThe Lancet, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986